Tumorigenesis is considered to be a multistep process where accumulation of several defects results in the deregulation of cell growth. In human testicular cancer these putative processes are poorly understood. Involvement of tumour suppressor genes that act in a recessive manner is suggested by loss of heterozygosity in some areas of the genome in tumour DNA (Lothe et al., 1989; Radice et al., 1989; Rukstalis et al., 1989; Peltomaki et al., 1990) . As cellular oncogenes are thought to participate in the regulation of cell differentiation -which is a prominent feature of testesalterations of oncogenes are of obvious interest in testicular tumours of germ cell origin. Mutation, rearrangement, and amplification are examples of molecular mechanisms that may lead to altered function through increased production of normal oncogene proteins or production of abnormal proteins.
The objective of the present investigation was to explore the involvement of oncogenes in testicular tumours. More specifically, we wished to determine (1) whether oncogene amplification occurs, (2) whether amplification resulted from polysomy of an entire chromosome arm or represented genespecific amplification, and (3) whether changes in DNA dosage were accompanied by altered gene expression. Results obtained in a series of 16 patients with testicular neoplasm are presented.
Materials and methods
Patients and samples The material was derived from 16 patients with sporadic testicular tumours. Histological diagnoses, clinical stages, and scrum levels of tumour markers are shown in Table I . Fourteen tumours were of germ cell and two of non-germ cell origin. A case (No. 10) of malacoplakia (a benign condition of unknown etiology which often results in a tumour-like formation in the testis) was included for comparison. In addition, we used the Tera-l cell line (No. HTB105, obtained at passage 51 from the American Type Culture Collection, ATCC). The line was established from a metastatic embryonal carcinoma by Fogh (1978) .
Samples of fresh tumour tissue, epididymis, and apparently normal testicular tissue as well as heparinised venous blood were obtained at the time of orchiectomy. The samples and case histories of patients 1-14 were described in greater detail previously (Peltomaki et al., 1989 and . Histologically, all the tumour and non-tumour samples could be considered representative (with the possible exception of the lymph node samples from patient 3; Peltomaki et al., 1989) .
As control samples for expression studies normal testicular tissue was obtained from six patients (all over 60 years) who underwent bilateral orchiectomies due to prostatic carcinoma.
Southern blot analysis High-molecular-weight DNA was extracted from blood and tissue samples by established methods (Kunkel et al., 1977;  (Mostofi & Sobin, 1977) . The corresponding British terminology (Pugh, 1976 ) is indicated in parentheses; bRoyal Marsden Hospital staging classification (Peckham, 1988) ; cOnly lymph node metastases studied. Maniatis et al., 1982) . Southern (1975) to nitrocellulose (Schleicher & Schuell, Dassel, Germany) or nylon (Zeta-Probe, Bio-Rad, Richmond, CA, USA) membranes. DNA probes were labelled with 32P by nick-translation (Rigby et al., 1977) or random primer synthesis (Feinberg & Vogelstein, 1984) . Prehybridisations and hybridisations were performed overnight in appropriate mixtures (as described by Bianchi et al., 1988; Peltomaki et al., 1989 Probes representing 14 oncogenes were utilised (Table II) . In addition, we used genomic probe pH 3-4 (Lalande et al., 1986) and cDNA probe p2R3.8 (Friend et al., 1986) In RNA studies cDNA probe pHcGAP (derived from the glyceraldehyde-3-phosphate dehydrogenase gene, Tso et al., 1985) was used as a quantitative standard. Expression levels were also standardised with genomic probe pHRL83-IVS4 (Gunning et al., 1984) . That represents the human cardiac actin gene locus but cross-hybridises with human P-actin mRNA. Probes pHcGAP and pHRL83-IVS4 were obtained from ATCC (depositors R. Wu and L. Kedes, respectively). Table II Tera-1 16 17 
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Figure 3 Blood (B) and tumour (T) DNA samples of patients 1 and 2, digested with EcoRI and hybridised and rehybridised with probes pmetH (representing MET), CK (a non-7q reference), and pNJ-3/3.5 (a 7q reference). The pmetH probe detects a fragment of about 2 kb and the CK probe a fragment of 2.5 kb. Probe pNJ-3/3.5 hybridises to allelic fragments of 13 and 3.5 kb.
PDGFB
An increase in the relative dosage of PDGFB (from 22q) appeared in patients 2 and 5 with germ cell neoplasm ( Figure  4 and Table III (see Materials and methods). The membrane was hybridised successively with probes representing the KRAS2 locus and the PDGFA locus and the hybridisation signals were compared to the V-actin mRNA levels. The relative expression of KRAS2 was clearly higher in tumours of patients 1, 5, 7, 9, 13, 14 and 15 than in tumours of patients 2, 6, and 8. On the contrary, PDGFA revealed only minor variation in expression between different samples. At rehybridisation of the blot with probe pHcGAP from the glyceraldehyde-3-phosphate dehydrogenase gene signal intensities directly proportional to those of the actin probe were obtained except in patients and 5 whose tumours showed clearly elevated mRNA levels (see below).
The essential similarity of expression levels in normal and tumour tissue of the same patient is exemplified by KRAS2 in Figure 6 . The tumour RNA samples (from three seminomas and three nonseminomas) shown in Figure 6 represent a part of a duplicate series of that presented in Figure 5 . The dot blot was hybridised with a KRAS2 probe (a) and rehybridised with probe pHcGAP from the glyceraldehyde-3-phosphate dehydrogenase gene (b) -both probes map to the short arm of chromosome 12. In the tumours of patients 1 and 5 there was an elevation in the expression of the glyceraldehyde-3-phosphate dehydrogenase gene accompanied by a smaller increase in KRAS2 expression in patient 1 and no increase in KRAS2 expression in patient 5. This obviously reflected the presence of one or several isochromosome 12p markers and correlated well with the Southern hybridisation results that showed the highest dosages of 12p in precisely these two tumours (see above). The membrane in Figures 6a and b was further hybridised with a probe derived from the retinoblastoma gene (c). It showed similar expression levels in normal and tumour samples of the patients except in patient 5 who revealed a higher retinoblastoma gene mRNA level in normal testis relative to his tumour. Figure 6d (hybridisation result obtained with the actin probe) shows that the lanes representing tumour and normal testicular tissue samples from patient 5 with expression changes of two different kinds contained roughly equal amounts of hybridisable RNA.
Discussion
At present only a few reports of oncogene alterations in human testis cancer exist. Cytogenetically a specific chromosome marker has been found in more than 80% of testicular germ cell tumours: an isochromosome for the short arm of chromosome 12 [i(12p)] (Castedo et al., 1988; Samaniego et al., 1990) . The i(12p) copy number has been reportd to have prognostic significance (Bosl et al., 1989) . It is not known, however, which of the genes carried by 12p are associated with the pathogenetic events in testicular cancer. The KRAS2 oncogene is one obvious candidate. The gene has been shown to be affected by point mutations or amplification in a wide variety of human tumours or tumour cell lines, including pancreas (Almoguera et al., 1988) , colon (Vogelstein et al., 1988) , and lung (Taya et al., 1984) . In seminoma tumours Mulder et al. (1989) found mutations at codons 12 or 61 of the KRAS2 gene (and the NRAS gene) with a frequency of 40%. These mutations were not, however, detected in human non-seminoma cell lines with increased copy numbers of 12p (Dmitrovsky et al., 1990) . Published reports of KRAS2 dosage and expression in testis cancer are mainly based on cell lines. Wang et al. (1987) and Dmitrovsky et al. (1990) observed 4-6-fold increases in KRAS2 dosage in non-seminoma cell lines relative to a non-12p reference locus. However, with a reference from 12p specific amplification of KRAS2 could not be demonstrated (Dmitrovsky et al., 1990) . Analogous findings were reported by Mulder et al. (1989) in primary seminomas. On the other hand, an increased gene dosage does not necessarily result in overexpression (Wang et al., 1987) and conversely, enhanced expression may occur without any evidence of amplification at the DNA level (Monnat et al., 1987) . Our present findings are generally consistent with the above observations and emphasise that control probes from the same chromosome should always be used.
The PDGFA and PDGFB genes encode A-and B-chains of the platelet-derived growth factor and are located on chromosome 7p and 22q, respectively. They are expressed independently of each other in human leukaemia and solid tumour cell lines as well as in certain normal cells (Betsholtz et al., 1986; Alitalo et al., 1987) . In a study of Slamon et al.
(1984) PDGFB transcripts were not found in any of 54 fresh human tumours, including one germ-cell tumour. EGFR in turn is shown to be amplified in human epidermoid carcinoma Hollstein et al., 1988) . Expression of EGFR is carefully regulated in normal cells, but its expression has been detected, apart from epidermoid carcinoma cells, in cell lines derived from the female urogenital system . In the present study detectable (up to 3-fold) increases in DNA dosage of PDGFA, PDGFB, or EGFR were observed in neoplastic tissue from a total of six patients out of 16. The signal enhancement in these cases exceeded that resulting from apparent aneuploidies of the respective chromosome arms (7p and 22q). As the tumours of the present series did not, however, reveal enhanced expression of PDGFA or EGFR in RNA dot blot assays the significance of the above amplifications remains unknown so far.
Other oncogenes reported to have been involved in testicular neoplasia include members of the myc family. Sikora et al. (1985) observed increased expression of MYC in seminomas. These authors also reported correlation between MYC expression and the grade of differentiation of a teratoma tumour: the more undifferentiated a teratoma the lower level of detectable c-myc protein. An elevated expression of MYCN (in the absence of gene amplification) was detected in one seminoma tumour by Saksela et al. (1989) . Definite alterations in the myc genes were not observed in the present study.
In addition to oncogenes, we studied the dosage and expression of the retinoblastoma susceptibility gene that represents tumour suppressor genes. Structural alterations and/or reduced expression of this gene have been observed, apart from retinoblastoma and osteosarcoma, in breast cancer (Lee et al., 1988) , small cell lung cancer (Harbour et al., 1988) , and also in a germ cell tumour of the testis (Saksela et al., 1989) . Two-fold or greater increases in dosage and expression of the retinoblastoma gene were in turn reported by Gope et al. (1990) in human colorectal carcinomas. Except for the finding of a lower level of expression in tumour vs normal tissue in a single case further evidence of the retinoblastoma gene playing a role in testis tumours did not come out in the present investigation.
There was a slight over-representation of nonseminoma and clinical stage greater than I, but no straightforward association of oncogene changes with the clinical stage or the histologic subtype was found in this tumour series. It is noteworthy that all primary tumours that produced elevated serum levels of tumour markers were also characterised by changes in oncogene dosage. Oncogene changes in the present study and allelic dosage changes reported previously (Peltomiiki et al., 1990) , though causally related in some cases, coexisted in several tumours. The situation is analogous to colon carcinoma where multiple steps -DNA hypomethylation, loss of alleles on chromosomes 5, 7 and 18, and activation of ras oncogenes -ultimately lead to a malignant phenotype (Vogelstein et al., 1988) .
